The Department of Health of Abu Dhabi, in the United Arab Emirates, said it has reached partnership agreements with Abbott, Boehringer Ingelheim (BI), and Sanofi, concurrent with a high-level delegation’s strategic mission to the United States from June 14–21, 2025 (1). This included a presence at the Biotechnology Innovation Organization (BIO) International Convention in Boston, from June 16–19, and visits to other major US cities including Philadelphia and Washington, DC (1).
Sharing knowledge, exploring investments
Key Takeaways
- Abu Dhabi signed MoUs with BI, Sanofi, and Abbott to expand vaccine R&D, local pharma production, and digital health capabilities.
- BI’s OpnME platform access aims to enhance Abu Dhabi’s clinical research by providing compounds, networks, and collaboration tools.
- Abbott’s pact focuses on localizing pharma manufacturing, biosimilar development, and advancing UAE’s digital health initiatives.
The intent of the mission, according to Abu Dhabi officials, is to reaffirm the Emirate’s position in worldwide healthcare innovation leadership, which the officials said is evidenced by its achievements in artificial intelligence, digital health, clinical research, and genomics—the latter area being one in which Abu Dhabi has said it is a leader in its global region (1). During the weeklong mission, the delegation planned more than 20 strategic meetings with both public and private sector leaders in the US for the purposes of exchanging knowledge and exploring investment opportunities.
“This mission reflects our commitment to shaping the future of health through collaboration, innovation, and shared purpose,” Her Excellency Dr. Noura Khamis Al Ghaithi, undersecretary of the Department of Health—Abu Dhabi, said in a press release (1). “Our vision is to build a health system that predicts, prevents, acts to restore, and acts to cure, therefore ensuring better outcomes for our communities and beyond. This can only be achieved through meaningful partnerships and a shared ambition to improve lives. We are proud to join our partners in the United States to explore new opportunities that advance healthcare, both in the UAE and globally.”
Deals struck with key industry players
As the mission progressed, the Department of Health made headway on several alliances with major companies. The first, announced June 16, was the signing of a memorandum of understanding (MoU) with BI primarily concerning the granting of access to, and harnessing the capabilities of, BI’s OpnME platform, which makes use of four flagship programs to enable the research community to access advanced compounds, expert networks, and other support and collaborative opportunities (2).